Company intelligence / Profile preview
ProteinQure
Toronto, Ontario, Canadaproteinqure.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Their novel Peptide Drug Conjugate (PDC) for triple-negative breast cancer demonstrated exceptional efficacy in Patient-Derived Xenograft (PDX) models, including against cancers resistant to standard chemotherapies and antibody-drug conjugates[5]
- Therapeutic areas
- Oncology
- Modalities
- PeptidesProtein-based drugsPeptide Drug Conjugates (PDCs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
David Cescon Lab at Princess Margaret Cancer Centre/University Health Network
Beyond the preview
Go deeper on ProteinQure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProteinQure.